Peptide Vaccines Guide: Cancer Neoantigens, COVID, and Personalized Immunotherapy

When most people think of vaccines, they picture protection against infectious diseases — polio, measles, influenza. But a second generation of vaccines is emerging that targets the body's own diseased cells rather than foreign pathogens. Peptide vaccines are at the center of this revolution, offering the precision to train the immune system against specific molecular targets — including cancer cells, persistent viral reservoirs, and even pathological proteins implicated in neurodegeneration.

The fundamental insight underlying peptide vaccines is that the immune system can be taught to recognize any peptide sequence — not just those from pathogens. If you can identify a peptide unique to a cancer cell (a "neoantigen"), you can, in principle, immunize a patient against their own tumor. This is the promise that has attracted billions in investment to peptide vaccine development over the past decade.

How Peptide Vaccines Work

Every cell in the body presents fragments of its own proteins on its surface through major histocompatibility complex (MHC) molecules — specifically MHC class I (displayed to cytotoxic CD8+ T cells) and MHC class II (displayed to helper CD4+ T cells). This presentation system normally allows immune surveillance: T cells constantly scan MHC-presented peptides and destroy cells displaying abnormal sequences.

Cancer cells accumulate mutations. Some of those mutations generate abnormal protein sequences — neoantigens — that are unique to tumor cells and absent from healthy tissue. Peptide vaccines exploit this by:

1. Identifying mutant peptide sequences specific to a patient's tumor through genomic sequencing
2. Synthesizing those peptide sequences
3. Injecting them (typically with an immune adjuvant) to prime the immune system
4. Training T cells to recognize and destroy cells presenting those peptides — i.e., the tumor cells

Because the neoantigens are unique to each patient's tumor, this approach is inherently personalized. No two patients receive the same vaccine.

Neoantigen Cancer Vaccines: The State of the Field

The clinical development of neoantigen cancer vaccines has accelerated dramatically since 2023, driven by positive Phase II/III data from multiple programs.

Moderna/Merck mRNA-4157 (V940): This is technically an mRNA vaccine encoding tumor neoantigens (the mRNA produces the peptide neoantigens inside cells), but it is conceptually identical to a peptide vaccine in its immunological mechanism. Combined with pembrolizumab (anti-PD-1 checkpoint inhibitor), mRNA-4157 showed a 44% reduction in risk of recurrence or death in resected high-risk melanoma compared to pembrolizumab alone in the KEYNOTE-942 Phase IIb trial. Phase III trials are ongoing. This is potentially the most important cancer vaccine data published in decades.

BioNTech BNT111: A fixed-combination mRNA cancer vaccine encoding four melanoma-associated antigens, in Phase II combined with cemiplimab. Unlike fully personalized neoantigens, BNT111 targets shared tumor antigens present in a subset of melanoma patients who express specific HLA types.

Gritstone bio SLATE: An off-the-shelf neoantigen vaccine using machine learning to identify neoantigens likely shared across patients with specific tumor types and HLA profiles. This approach trades some personalization for scalability and faster manufacturing.

NEC/Neos personalized peptide vaccines (Japan): Japan has the most mature clinical experience with personalized peptide vaccines, having run dozens of trials over two decades. Several Phase III programs in glioblastoma, colorectal, and lung cancer are ongoing.

The Manufacturing Challenge of Personalized Vaccines

A central challenge of personalized peptide cancer vaccines is manufacturing speed and cost. The clinical workflow looks like this:

1. Patient's tumor is surgically resected or biopsied
2. Tumor DNA and RNA are sequenced (1–2 weeks)
3. Computational algorithms identify neoantigen candidates (1–3 days)
4. Peptides are synthesized at clinical grade (2–4 weeks)
5. Vaccine is released after quality control testing (1–2 weeks)
6. Vaccine is administered (typically starting within 6–12 weeks of surgery)

This timeline is manageable for adjuvant settings (post-surgery) where patients are disease-free and waiting, but more challenging for active disease settings where tumor growth during the manufacturing window is a concern. Reducing synthesis and QC timelines is an active area of development.

Synthesis cost per patient is currently $50,000–$150,000 for a full personalized peptide vaccine course, which is a significant barrier to broad access. Automation of peptide synthesis and QC, driven partly by AI peptide discovery methods, is expected to reduce costs substantially over the next five years.

COVID-19 Peptide Vaccines and T Cell Immunity

The COVID-19 pandemic generated enormous research interest in T cell immunity and the role of peptide epitopes in lasting viral protection. While the authorized COVID vaccines are mRNA or adenoviral vector-based, extensive research has characterized which SARS-CoV-2 peptides are most immunogenic across diverse HLA types.

This research has practical implications. Individuals who had mild or asymptomatic COVID-19 often show strong CD8+ T cell responses to internal viral proteins (nucleocapsid, membrane protein) in addition to spike-specific responses. These T cell responses appear more durable and cross-reactive across variants than antibody responses, which wane quickly and are variant-specific.

VaxEquity's CD8 T cell epitope vaccines: Designed specifically to elicit cytotoxic T cell responses against conserved coronavirus peptide epitopes that are less susceptible to variant evolution. These are in Phase I/II as pan-coronavirus "T cell vaccines."

CoVLP (Medicago, plant-derived VLP): Uses virus-like particles displaying peptide antigens in their native conformational context. The VLP scaffold improves immunogenicity compared to free peptides.

The COVID vaccine research has broadly validated the concept that peptide-based vaccines can be designed rapidly, manufactured efficiently, and generate protective immunity — a foundation that benefits the entire peptide vaccine field.

Peptide Vaccines for Alzheimer's Disease

Amyloid beta (Aβ) and tau protein — the two pathological proteins implicated in Alzheimer's disease — are attractive targets for peptide vaccines. The concept: train the immune system to clear Aβ plaques and tau tangles before they cause irreversible neurodegeneration.

AN1792 (Elan Pharmaceuticals) was the first Aβ peptide vaccine to reach clinical trials, in 2001. The trial was halted when 6% of patients developed meningoencephalitis — severe brain inflammation — apparently caused by excessive T cell responses against full-length Aβ peptide. This taught the field that Aβ vaccines need to specifically elicit antibody responses (B cell epitopes) without activating T cell responses (T cell epitopes).

Second-generation Aβ vaccines (CAD106, ABvac40, Lu AF20513) use truncated or modified Aβ peptides that contain B cell epitopes but lack T cell epitopes, producing anti-amyloid antibodies without T cell-mediated brain inflammation. Phase II/III data from these programs is under analysis.

Tau peptide vaccines targeting phosphorylated tau epitopes are in Phase I/II, with the rationale that anti-tau immunity could slow neurofibrillary tangle progression.

Adjuvants: Making Peptide Vaccines More Immunogenic

Peptide vaccines face an inherent challenge: short, synthetic peptides are often weakly immunogenic on their own. The immune system doesn't mount a strong response to isolated peptides the way it does to whole pathogens. Adjuvants — immune stimulants co-administered with the antigen — are essential components of peptide vaccine formulations.

Montanide ISA 51 and ISA 720: Water-in-oil and oil-in-water emulsion adjuvants widely used in cancer peptide vaccine trials. Create a depot at the injection site and stimulate innate immunity.

CpG oligonucleotides (TLR9 agonists): Synthetic DNA sequences that activate Toll-like receptor 9, a pattern recognition receptor for bacterial DNA. Potent CD8+ T cell adjuvants, critical for therapeutic cancer vaccines.

Poly-ICLC (Hiltonol): A TLR3/MDA5 agonist that mimics double-stranded RNA (normally a sign of viral infection). Used in glioblastoma peptide vaccine trials with promising immunogenicity data.

Newer liposomal adjuvant systems: Lipid nanoparticles combined with TLR agonists provide simultaneous antigen delivery and immune stimulation, improving vaccine efficiency.

Peptide Vaccines for Infectious Disease Beyond COVID

Several infectious disease peptide vaccine programs have advanced beyond COVID research:

HIV therapeutic vaccines: Long-term HIV-infected individuals on antiretroviral therapy have been vaccinated with conserved HIV peptide epitopes to build T cell immunity that could control viral rebound upon ART interruption. Phase II results have shown enhanced T cell responses but inconsistent virologic control.

Malaria SPf66: The first malaria vaccine was a synthetic peptide vaccine (though with limited efficacy). Modern malaria vaccine development has moved toward protein subunit and mRNA approaches, but peptide epitope research informs these programs.

CMV peptide vaccines: Cytomegalovirus (CMV) is a significant risk in transplant recipients and immunocompromised patients. Peptide vaccines targeting highly conserved CMV T cell epitopes are in clinical development.

Frequently Asked Questions

Q: Are personalized cancer vaccines the same as CAR-T cell therapy? No. Personalized cancer vaccines train your existing immune system (T cells and B cells) to recognize tumor neoantigens. CAR-T cell therapy takes your T cells out of the body, genetically engineers them to express a chimeric antigen receptor targeting a specific tumor protein, and infuses them back. Both are immunotherapy, but they work through different mechanisms.

Q: Can peptide vaccines prevent cancer, or only treat it? Currently, most peptide cancer vaccines are therapeutic — designed to treat existing tumors or prevent recurrence. Preventive cancer vaccines (prophylactic) would require identifying peptide targets present before cancer develops. The HPV vaccine, which prevents cervical cancer by preventing a viral infection, is a successful prophylactic cancer vaccine, but it targets a virus rather than a cancer peptide.

Q: How do researchers identify which neoantigens to target in a personalized vaccine? Tumor genomic sequencing identifies point mutations. Algorithms then predict which mutant peptides will be presented on the patient's specific HLA alleles (each person has a unique set of HLA molecules that bind different peptide sequences). Peptides predicted to bind strongly and to be expressed in the tumor are prioritized for vaccine inclusion.

Q: What is the difference between a peptide vaccine and an mRNA cancer vaccine? An mRNA vaccine encodes the peptide antigen as RNA instructions — cells make the peptide from the mRNA. A traditional peptide vaccine delivers the peptide directly. Both can produce similar immune responses; mRNA is easier to manufacture rapidly and can encode multiple antigens, while direct peptide delivery offers precise control over which exact peptide sequence is administered.

Q: Why haven't peptide cancer vaccines been approved yet if the data looks promising? The mRNA-4157/V940 program (Moderna/Merck) is the closest to potential approval, with Phase III ongoing. Approval requires demonstrating statistically significant benefit in large Phase III trials. Several earlier peptide cancer vaccine programs showed promising Phase II data that did not replicate in Phase III — a common problem in oncology drug development. The improved results with checkpoint inhibitor combinations may be what finally pushes personalized cancer vaccines over the approval threshold.